Abstract: This invention relates to the field of chemical pharmaceutical industry, namely, to pharmaceutical formulations for preparation of prolonged release tablets, in particular, tablets for sublingual application, and to methods of preparation of such formulations. Pharmaceutical formulation comprises 96.0 to 99.8% wt. of the pharmaceutical drug microcapsules, 0.1 to 1% wt. of lubricant, and 0.1 to 3% wt. of water, each microcapsule comprising 96.0 to 99.2% wt. of the pharmaceutical drug and 0.8 to 4% wt. of film-forming substance. Dispersant is also introduced into formulation in the amount of 0.1 to 10% wt. of the total mixture obtained. Method of preparation of the pharmaceutical formulation comprises preparation of microcapsules by deposition of coating of film-forming substance on non-agglomerated particles of pharmaceutical drug, and addition of lubricant and dispersant.

Abstract: A method is described for preparing a mixture for quality control of 0.1 g glycine tablets for sublingual application. The mixture for quality control includes a 100:0.5 ratio of ethanol to porphyrized tablets, each tablet containing 0.1 g microcapsules of non-agglomerated crystals of amino-acetic acid covered with a polymeric film of water-soluble methylcellulose, each tablet further containing 0.001 g of magnesium stearate. The process for preparing the mixture includes dissolution of the tablet in ethanol for 20 minutes and is carried out at a temperature of 40° C. in an apparatus using a paddle rotation speed of 200 revolutions per minute. After the mixture is dissolved, it is allowed to stand for 10 minutes at room temperature, and then a light transmission coefficient is measured at 700±2 nm for a 10 mm thick layer of the mixture. A transmission value within the limits of 90% to 100% compared with 50% ethanol corresponds to the proper quality.

Abstract: The task of this invention is in use of composition containing natural metabolites—amino acids, and in method of its administration which make it possible to increase skin repigmentation through sulfurcontaining compounds rise and activation of endogenic metabolic reactions, and to get persistent normalization of melanogenesis thus improving skin integument and as a consequence patient's quality of life. Composition includes L cystine, L glutamic acid and glycine in the following quantity, mg: L cystine 85 ± 10%, L glutamic acid 85 ± 10%, Glycine 85 ± 10% The amino acid composition mentioned above must be administered 3 times a day for 5 weeks independent of meal in accordance with method of increase of skin integument repigmentation in vitiligo. The course can be repeated in 4-5 weeks.

Abstract: The invention relates to the chemical-pharmaceutical industry and specifically to mix for identification test in the process of quality control of the medicine ‘Glycine tablets for sublingual applying 0.1 g.’ its preparation method and method of identity evaluation in the process of quality control of the mentioned medicine. There is prepared mix containing 50% etha??l and porphyrized tablets in a ratio 100:0.5. The method involves dissolution of 1.25 g of porphyrized tablets in 250 ml of 50% ethanol. Process of dissolution takes 20 minutes and is carried out at a temperature of 400 C in the apparatus for dissolving determination at a paddle rotation speed of 200 rpm. After mix is dissolved it is allowed for 10 minutes RT. Method of identification test includes hydro-alcohol mix preparation using 50% ethanol as described before. Then there are selected 4 ml of the mix for light transmission spectrophotometer analysis at a wave length of 700±2 in a cuvet with layer thickness of 10 mm relative to 50% ethanol.

Abstract: A method is described for preparing a mixture for quality control of 0.1 g glycine tablets for sublingual application. The mixture for quality control includes a 100:1 ratio of water to porphyrized tablets, each tablet containing 0.101 g microcapsules of non-agglomerated crystals of amino-acetic acid covered with polymeric film of water-soluble methylcellulose, each tablet further comprising 0.001 g magnesium stearate. The process of dissolution takes 20 minutes and is carried out at a temperature of 37° C. in an apparatus using a paddle rotation speed of 150 revolutions per minute. After the mixture is dissolved, it is allowed to stand for 10 minutes, then a light transmission coefficient is measured at 700±2 nm for a 10 mm thick layer of the mixture. A transmission value within the range of 50% to 70% compared to purified water corresponds to the proper quality.

Abstract: The invention relates to the chemical-pharmaceutical industry and specifically to mix for quality control of the medicine “Glycine tablets for sublingual applying 0.1” and its preparation method. The method involves process of analysis by dissolution of 2.5 g of porphyrized tablets in 250 ml of purified water and light transmission spectrophotometer examination at a wave length of 700±2 in a cuvet with layer thickness of 10 mm relative to purified water Process of dissolution takes 20 minutes and is carried out at a temperature of 370° C. in the apparatus for dissolving determination at a paddle rotation speed of 150 rpm. After mix is dissolved it is allowed for 10 minutes then there are selected 4 ml for light transmission analysis. Mix for quality control includes water in a ratio 100:1 to porphyrized tablets, containing in one tablet 0.101 g microcapsules of non-agglomerated crystals of amino-acetic acid covered with polymeric film of water-soluble methylcellulose, MC-100 and 0.001 g of magnesium stearate.

Abstract: This invention relates to the field of chemical pharmaceutical industry, namely, to pharmaceutical formulations for preparation of prolonged release tablets, in particular, tablets for sublingual application, and to methods of preparation of such formulations. Pharmaceutical formulation comprises 96.0 to 99.8% wt. of the pharmaceutical drug microcapsules, 0.1 to 1% wt. of lubricant, and 0.1 to 3% wt. of water, each microcapsule comprising 96.0 to 99.2% wt. of the pharmaceutical drug and 0.8 to 4% wt. of film-forming substance. Dispersant is also introduced into formulation in the amount of 0.1 to 10% wt. of the total mixture obtained. Method of preparation of the pharmaceutical formulation comprises preparation of microcapsules by deposition of coating of film-forming substance on non-agglomerated particles of pharmaceutical drug, and addition of lubricant and dispersant.